Control group:Camrelizumab + chemotherapy

2 trials

Sponsors

Shandong Provincial Hospital, Shanghai Ninth People's Hospital, Shanghai JiaoTong University School of Medicine

Conditions

Non-small cell lung cancerPathologically diagnosed squamous cell carcinoma, primary head and neck tumor of clinical stage III-IVb (AJCC 8th edition) (excluding nasopharyngeal cancer).

Phase 4

Camrelizumab combined with chemotherapy and SBRT+LDRT in first-line treatment of advanced non-small cell lung cancer with negative PD-L1 expression

Active, not recruitingChiCTR2400091543

Shandong Provincial HospitalNon-small cell lung cancer

Start: 2024-10-30Updated: 2024-11-04

Randomized Controlled Trial of Camrelizumab Combined with EGFR Monoclonal Antibody or Chemotherapy for Perioperative Treatment of Locally Advanced Head and Neck Squamous Cell Carcinoma

Active, not recruitingChiCTR2600119577

Shanghai Ninth People's Hospital, Shanghai JiaoTong University School of MedicinePathologically diagnosed squamous cell carcinoma, primary head and neck tumor of clinical stage III-IVb (AJCC 8th edition) (excluding nasopharyngeal cancer).

Start: 2026-03-01Updated: 2026-03-02